Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934694 | 0.88 | USP2 (0.51) | HSD17B10USP2TDP1HTTPLA2G4B | |
| SCHEMBL17933338 | 0.85 | HSD17B10 (0.50) | HSD17B10USP2TDP1HTTPLA2G4B | |
| SCHEMBL1063048 | 0.85 | USP2 (0.62) | USP2HTTPLA2G4BMEN1KMT2A | |
| SCHEMBL9716396 | 0.85 | USP2 (0.62) | USP2HTTPLA2G4BMEN1KMT2A | |
| SCHEMBL14865731 | 0.83 | USP2 (0.50) | HSD17B10USP2HTTPLA2G4BMEN1 | |
| SCHEMBL14865692 | 0.80 | PLA2G4B (0.55) | HSD17B10USP2TDP1HTTPLA2G4B | |
| SCHEMBL21676039 | 0.80 | USP2 (0.42) | HSD17B10USP2TDP1HTTPLA2G4B | |
| SCHEMBL10635148 | 0.80 | USP2 (0.38) | USP2TDP1HTTPLA2G4B | |
| SCHEMBL11281098 | 0.79 | ROCK2 (0.32) | TDP1 | |
| SCHEMBL16475510 | 0.79 | ROCK2 (0.41) | TDP1PLA2G4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530559-B2 | Composite of organic compound and copper nanoparticles, composite of organic compound and copper(I) oxide nanoparticles, and methods for producing the composites | DIC CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130095320-A1 | COMPOSITE OF ORGANIC COMPOUND AND COPPER NANOPARTICLES, COMPOSITE OF ORGANIC COMPOUND AND COPPER(I) OXIDE NANOPARTICLES, AND METHODS FOR PRODUCING THE COMPOSITES | DIC CORPORATION (JP) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095320-A1 | COMPOSITE OF ORGANIC COMPOUND AND COPPER NANOPARTICLES, COMPOSITE OF ORGANIC COMPOUND AND COPPER(I) OXIDE NANOPARTICLES, AND METHODS FOR PRODUCING THE COMPOSITES | AOC3, AOC2, CORO1C | HSD17B10 2100/4885USP2 883/4885TDP1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.